Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10201/22674

Título: Perioperative IFN-a to avoid surgically induced immune suppression in colorectal cancer patients
Fecha de publicación: 2006
Editorial: Murcia : F. Hernández
ISSN: 0213-3911
Materias relacionadas: CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología
Palabras clave: Surgery
Colorectal cancer
Resumen: Surgical treatment of colorectal cancer is associated with postoperative immunosuppression, which might facilitate dissemination of tumor cells and outgrowth of minimal residual disease/(micro) metastases. Minimal residual disease has been shown to be of prognostic relevance in colorectal cancer. Therefore, stimulation of (anti-tumor) immune responses may be beneficial in the prevention of metastases formation. Important anti-tumor effector cells, which serve this function, are natural killer (NK) cells, CD8+ lymphocytes (CTL), dendritic cells (DC) and macrophages. In this review the immunomodulating properties of IFN-a are discussed, with a particular focus on perioperative stimulation of immune function in cancer patients. IFN-a is known to enhance innate immune functions such as stimulation of NK cells, transition from innate to adaptive responses (activation of DC) and regulating of CD8+ CTL activity and memory. Moreover, it exerts direct antitumor effects by regulating apoptosis and cell cycle. In several clinical trials, perioperative administration of IFN-a has indeed been shown to improve T cell responsiveness, prevent impairment of NK cell cytotoxicity and increase expression of activation markers on NK, T and NKT cells. In a clinical pilot study we showed in colorectal cancer patients that received perioperative IFN-a enhanced activation markers on T cells and NK cells, combined with betterpreserved T cell function as indicated by phytohemaggluttinin skin tests. In the liver of these patients significantly more CD8+ T cells were found. In conclusion, IFN-a provides an effective adjuvant in several forms of cancer and improves several postoperative immune functions in perioperative administration. However, larger clinical trials are necessary to investigate effects on disease-free and overall survival.
Autor/es principal/es: Oosterling, S.J.
van der Bij, G.J.
Mels, A.K.
Beelen, R.H.J.
Meijer, S.
van Egmond, M.
van Leeuwen, P.A.M.
Publicado en: Histology and histopathology
URI: http://hdl.handle.net/10201/22674
Tipo de documento: info:eu-repo/semantics/article
Número páginas / Extensión: 8
Derechos: info:eu-repo/semantics/openAccess
Aparece en las colecciones:Vol.21, nº 7 (2006)

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
Perioperative IFNa to avoid surgically induced immune suppression.pdf4,58 MBAdobe PDFVista previa

Los ítems de Digitum están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.